US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zealand Pharma A/S

62.10

0.0000

Volume:165.00

Turnover:10.22K

Market Cap:4.41B

PE:-34.36

High:62.10

Open:62.10

Low:62.10

Close:62.10

52wk High:108.30

52wk Low:49.98

Shares:70.94M

Float Shares:60.58M

Volume Ratio:0.05

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8072

EPS(LYR):-1.8442

ROE:54.42%

ROA:33.44%

PB:1.97

PE(LYR):-33.67

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Zealand Pharma A/S

Exchange:

PINK LIMITED

Establishment Date:

1997

Employees:

440

Office Location:

Sydmarken 11,Søborg,Capital Region of Denmark,Denmark

Website:

http://www.zealandpharma.com

Zip Code:

2860

Phone:

Fax:

45 88 77 38 98

Introduction:

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZLDPF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZLDPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","market":"US","secType":"STK","nameCN":"Zealand Pharma A/S","latestPrice":62.1,"timestamp":1771439589791,"preClose":62.1,"halted":0,"volume":165,"delay":15,"changeRate":0,"floatShares":60575983,"shares":70935412,"eps":-1.807241,"marketStatus":"Post-Mkt","change":0,"latestTime":"02-18 13:33:09 EST Delay","open":62.1,"high":62.1,"low":62.1,"amount":10221.5,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.807241,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":62.1,"volumeRatio":0.049254},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","floatShares":60575983,"roa":"33.44%","roe":"54.42%","lyrEps":-1.844231,"volumeRatio":0.049254,"shares":70935412,"dividePrice":0,"high":62.1,"amplitude":0,"preClose":62.1,"low":62.1,"week52Low":49.98,"pbRate":"1.97","psRate":"3.27","week52High":108.3,"institutionHeld":0,"latestPrice":62.1,"eps":-1.807241,"divideRate":0,"volume":165,"delay":15,"ttmEps":-1.807241,"open":62.1,"prevYearClose":71.6,"prevWeekClose":63.84,"prevMonthClose":67.28,"prevQuarterClose":71.6,"fiveDayClose":64.075,"twentyDayClose":63,"sixtyDayClose":78.7776},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZLDPF\",params:#limit:5,,,undefined,":[{"date":"2024-05-16","symbol":"ZLDPF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715846400000,"name":null,"time":"Pre-Market","dateTimestamp":1715832000000,"actualEps":null},{"market":"US","date":"2022-11-10","symbol":"ZLDPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668056400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZLDPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZLDPF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1268514,"yearFounded":1997,"employeeNum":440,"address":"Sydmarken 11,Søborg,Capital Region of Denmark,Denmark","zipCode":"2860","officePhone":"45 88 77 36 00","officeFax":"45 88 77 38 98"},"stockCompanyDetail":{"websiteUrl":"http://www.zealandpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0569},{"period":"6month","weight":0.7055},{"period":"1year","weight":0.2545},{"period":"ytd","weight":0.9409}],"description":"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.","exchange":"PINK LIMITED","name":"Zealand Pharma A/S","nameEN":"Zealand Pharma A/S"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ZLDPF\",market:\"US\",,,undefined,":null}}